Glomerular disease in 2014: advances in basic science and translational medicine
- PMID: 25584803
- DOI: 10.1038/nrneph.2014.248
Glomerular disease in 2014: advances in basic science and translational medicine
Abstract
Knowledge of the pathogenesis of glomerular disease and approaches to therapy continued to advance in 2014. Key studies identified thrombospondin type-1 domain-containing protein 7A as an antigenic target in primary membranous nephropathy, and demonstrated efficacy of rituximab as maintenance therapy in relapsing or steroid-dependent nephrotic syndrome and antineutrophil cytoplasmic antibody-associated vasculitis.
Similar articles
-
Management of glomerular diseases of primary and secondary origin.Curr Opin Nephrol Hypertens. 1992 Oct;1(1):124-32. doi: 10.1097/00041552-199210000-00018. Curr Opin Nephrol Hypertens. 1992. PMID: 1365824 Review.
-
Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases.Nefrologia. 2014 May 21;34(3):388-97. doi: 10.3265/Nefrologia.pre2014.Feb.12506. Epub 2014 Apr 10. Nefrologia. 2014. PMID: 24798567 Review. English, Spanish.
-
[Rationale and clinical evidence for the use of rituximab in glomerular diseases].Rev Med Suisse. 2011 Apr 13;7(290):819-24. Rev Med Suisse. 2011. PMID: 21595313 Review. French.
-
Advances in the pathology of glomerular diseases.Contrib Nephrol. 2013;181:12-21. doi: 10.1159/000348639. Epub 2013 May 8. Contrib Nephrol. 2013. PMID: 23689563 Review.
-
[Case of MPO-ANCA-associated vasculitis with membranous nephropathy].Nihon Jinzo Gakkai Shi. 2011;53(1):46-52. Nihon Jinzo Gakkai Shi. 2011. PMID: 21370577 Japanese.
Cited by
-
A mild form of rituximab-associated lung injury in two adolescents treated for nephrotic syndrome.BMJ Case Rep. 2015 Dec 9;2015:bcr2015212694. doi: 10.1136/bcr-2015-212694. BMJ Case Rep. 2015. PMID: 26661285 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical